https://www.southampton.ac.uk/shtac/news/latest.pageSHTAC News FeedSHTAC are recruiting a Research Fellow in Health Technology Assessment & Modellinghttps://cdn.southampton.ac.uk/assets/imported/transforms/site/news-release/PageThumbnail/2A855A02AAC64518800BC19F79F0D44B/join our team resized.jpg_SIA_JPG_fit_to_width_XL.jpghttps://www.southampton.ac.uk/shtac/news/2019/11/4researchfellowinhe.pageThis is a fixed term position to 31 March 2022. Full time or part time will be considered. SHTAC are seeking a researcher with exceptional analytical and communication skills to join our team supporting national health policy decisions about the effective and cost-effective use of medicines and other healthcare technologies.https://www.southampton.ac.uk/shtac/news/2019/11/4researchfellowinhe.pageMon, 04 Nov 2019 00:00:00 +0000NICE guidance informed by SHTAC report on rivaroxaban for preventing major cardiovascular events in people with coronary or peripheral artery diseasehttps://cdn.southampton.ac.uk/assets/imported/transforms/site/news-release/PageThumbnail/984E95CF134049DEAA14C945D1C2301C/heart1.jpg_SIA_JPG_fit_to_width_XL.jpghttps://www.southampton.ac.uk/shtac/news/2019/10/rivaroxaban-for-majorcardiovascularevents.pageThe National Institute for Health and Care Excellence (NICE) has issued guidance to the National Health Service (NHS) on the use of the Rivaroxaban plus aspirin, for preventing atherothrombotic events, informed by a report produced by SHTAC. NICE’s guidance recommends Rivaroxaban (Xarelto) with aspirin within its marketing authorisation as a possible treatment for preventing atherothrombotic events (such as stroke or heart attack) in adults who are at high risk because they have:https://www.southampton.ac.uk/shtac/news/2019/10/rivaroxaban-for-majorcardiovascularevents.pageThu, 17 Oct 2019 00:00:00 +0100SHTAC are recruiting a Research Fellow in Evidence Synthesishttps://cdn.southampton.ac.uk/assets/imported/transforms/site/news-release/PageThumbnail/2A855A02AAC64518800BC19F79F0D44B/join our team resized.jpg_SIA_JPG_fit_to_width_XL.jpghttps://www.southampton.ac.uk/shtac/news/2019/09/10-9-19-recruitment.pageThis is a 12 month fixed term maternity cover position. Full time or part time will be considered. We are seeking a person with good knowledge of, and/or demonstrable skills in conducting systematic reviews to join our team supporting national health policy decisions about the effectiveness and cost-effective use of medicines and other healthcare technologies. https://www.southampton.ac.uk/shtac/news/2019/09/10-9-19-recruitment.pageTue, 10 Sep 2019 00:00:00 +0100SHTAC is presenting at the Health Technology Assessment (HTA) International conference, Cologne, 18th June 2019https://cdn.southampton.ac.uk/assets/imported/transforms/site/news-release/PageThumbnail/C9647BA08F794D85ACE0C1194142A877/research graphic news.jpg_SIA_JPG_fit_to_width_XL.jpghttps://www.southampton.ac.uk/shtac/news/2019/06/18-htai-conference-2019.pageThe oral presentation, given by Dr Jonathan Shepherd, will describe the scope, methods and findings of a recently completed systematic map conducted by researchers at SHTAC.https://www.southampton.ac.uk/shtac/news/2019/06/18-htai-conference-2019.pageTue, 18 Jun 2019 00:00:00 +0100NICE guidance informed by SHTAC report on atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer https://cdn.southampton.ac.uk/assets/imported/transforms/site/news-release/PageThumbnail/F4E8ECFC0EA54597AB2E37ACD5D8B39E/lung cancer.jpg_SIA_JPG_fit_to_width_XL.jpghttps://www.southampton.ac.uk/shtac/news/2019/06/5-nice-guidance-informed-by-shtac-report.pageThe National Institute for Health and Care Excellence (NICE) has issued guidance to the National Health Service (NHS) on the use of the atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer, informed by a report produced by SHTAC. https://www.southampton.ac.uk/shtac/news/2019/06/5-nice-guidance-informed-by-shtac-report.pageWed, 05 Jun 2019 00:00:00 +0100